These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27761881)

  • 21. Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus.
    Hayakawa T; Kato KI; Kobuchi S; Kataoka K; Sakaeda T
    Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.
    Brunton SA
    Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study.
    Kaku K; Maegawa H; Tanizawa Y; Kiyosue A; Ide Y; Tokudome T; Hoshino Y; Yang J; Langkilde AM
    Diabetes Ther; 2014 Dec; 5(2):415-33. PubMed ID: 25341477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study.
    Tamez-Perez HE; Delgadillo-Esteban E; Soni-Duque D; Hernández-Coria MI; Tamez-Peña AL
    J Diabetes Metab Disord; 2017; 16():27. PubMed ID: 28680862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expert Opinion About the Pharmacoeconomic Edge of Low-Cost Dapagliflozin in Type 2 Diabetes Mellitus in Indian Clinical Settings.
    Sharma K; Chandorkar AB; Kovil R; Venkataraman S; Subrahmanyam K; Mandal P; Wasir J; Abhyankar M; Prasad A; Sarda PS
    Cureus; 2021 Nov; 13(11):e19194. PubMed ID: 34877189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EMPAGLIFLOZIN IS MORE EFFECTIVE IN REDUCING MICROALBUMINURIA AND ALT LEVELS COMPARED WITH DAPAGLIFLOZIN: REAL LIFE EXPERIENCE.
    Gunhan HG; Imre E; Erel P; Ustay O
    Acta Endocrinol (Buchar); 2020; 16(1):59-67. PubMed ID: 32685040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional annotation and enrichment analysis of differentially expressed serum proteins in patients with type 2 diabetes after dapagliflozin.
    Zhao YX; Borjigin S; Yan ZL
    World J Diabetes; 2022 Mar; 13(3):224-239. PubMed ID: 35432754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of voglibose on the pharmacokinetics of dapagliflozin in Japanese patients with type 2 diabetes.
    Imamura A; Kusunoki M; Ueda S; Hayashi N; Imai Y
    Diabetes Ther; 2013 Jun; 4(1):41-9. PubMed ID: 23307267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study.
    Lee PCH; Gu Y; Yeung MY; Fong CHY; Woo YC; Chow WS; Tan K; Lam KSL
    Diabetes Ther; 2018 Feb; 9(1):285-295. PubMed ID: 29322486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Possible Novel Effect for Dapagliflozin in the Management of Subcutaneous Insulin Resistance Syndrome: A Report of Two Cases.
    Sweis NWG; Albanna A; Alhasoun R; Zayed A
    Int J Endocrinol Metab; 2022 Jul; 20(3):e126350. PubMed ID: 36407033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes.
    Evans M; Hicks D; Patel D; Patel V; McEwan P; Dashora U
    Diabetes Ther; 2020 Jan; 11(1):37-52. PubMed ID: 31813092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study.
    Scheerer MF; Rist R; Proske O; Meng A; Kostev K
    Diabetes Metab Syndr Obes; 2016; 9():337-345. PubMed ID: 27822077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effıcacy and safety of dapagliflozin on diabetic patients receiving high-doses of insulin.
    Sertbas M; Sertbas Y; Okuroglu N; Akyildiz AB; Sancak S; Ozdemir A
    Pak J Med Sci; 2019; 35(2):399-403. PubMed ID: 31086522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Study Protocol for the Effects of Formula Diet with Dapagliflozin on Metabolic Improvement and Body Composition in Type 2 Diabetes Mellitus.
    Watanabe Y; Kuribayashi N; Uchida D; Suzuki D; Kato M; Nagayama D; Ohashi H; Ohira M; Saiki A; Tatsuno I
    Diabetes Ther; 2019 Feb; 10(1):311-321. PubMed ID: 30574667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Outcomes of Dapagliflozin Use in Real-Life Clinical Settings in Endocrinology Clinics of Islamabad, Pakistan.
    Kamin M; Ishtiaq O; Raashid K; Wahab MU; Khan SA; Raja U
    Cureus; 2020 Jun; 12(6):e8565. PubMed ID: 32550088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Dapagliflozin in Southern Europe Across the Spectrum of Characteristics of Type 2 Diabetes: An International Real-World Analysis.
    Fadini GP; Morales C; Caballero I; González B; Tentolouris N; Consoli A
    Diabetes Metab Syndr Obes; 2022; 15():3533-3541. PubMed ID: 36411790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Multinational Real-World Study on the Clinical Characteristics of Patients with Type 2 Diabetes Initiating Dapagliflozin in Southern Europe.
    Fadini GP; Tentolouris N; Caballero Mateos I; Bellido Castañeda V; Morales Portillo C
    Diabetes Ther; 2020 Feb; 11(2):423-436. PubMed ID: 31863344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Audit of Insulin Usage and Insulin Injection Practices in a Large Indian Cohort.
    Baruah MP; Kalra S; Bose S; Deka J
    Indian J Endocrinol Metab; 2017; 21(3):443-452. PubMed ID: 28553603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Clinical Outcomes With the V-Go Wearable Insulin Delivery Device in Patients With Type 2 Diabetes.
    Meade LT; Battise D
    Clin Diabetes; 2021 Jul; 39(3):297-303. PubMed ID: 34421206
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.